FY25 net profit beat expectations due to higher other income and a lower tax outgo, EBITDA came in slightly below estimates because of increased R&D expenditure.

Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...